BioCurex’s RECAF technology complements the recent acquisition of Matritech and the equity investment in Diamics and should enhance our product development efforts in these areas,” said Ferran Prat, VP of Oncology for Inverness Medical Innovations. “As only the second diagnostic manufacturer with access to RECAF, this agreement represents an important competitive step for Inverness within the oncology diagnostics and monitoring markets.”